Mycoplasma pneumoniae pneumonia in children

Korean Journal of Pediatrics

Volumn 55, Issue 2, 2012, Pages 42-47

  Youn, You Sook ^a   Lee, Kyung Yil ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Child; Corticosteroids; Drug resistance; Macrolides; Mycoplasma pneumoniae; Pneumonia

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CORTICOSTEROID; ERYTHROMYCIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 8; MACROLIDE; MEPREDNISONE; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; ROXITHROMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; HUMAN; IMMUNOPATHOGENESIS; LOWER RESPIRATORY TRACT INFECTION; MACROLIDE RESISTANT MYCOPLASMA PNEUMONIAE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; POLYMERASE CHAIN REACTION; RESPIRATORY DISTRESS; T LYMPHOCYTE ACTIVATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84930480008     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2012.55.2.42     Document Type: Article

References (53)

1. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical mani festations, pathogenesis and laboratory detection of Mycoplasma pneu moniae infections. FEMS Microbiol Rev 2008;32:956-73.
2. Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008;6:509-21.
3. Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of myco plasmas. Microbiol Mol Biol Rev 1998;62:1094-156.
4. Denny FW, Clyde WA Jr, Glezen WP. Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control. J Infect Dis 1971;123:74-92.
5. Shimizu T, Kida Y, Kuwano K. Cytoadherence-dependent induction of inflammatory responses by Mycoplasma pneumoniae. Immunology 2011;133:51-61.
6. Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR, et al. Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneu moniae strains. Am J Respir Crit Care Med 2010;182:797-804.
7. Chang HY, Jordan JL, Krause DC. Domain analysis of protein P30 in Mycoplasma pneumoniae cytadherence and gliding motility. J Bacteriol 2011;193:1726-33.
8. Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med 1986;110:34-41.
9. Vuori-Holopainen E, Salo E, Saxén H, Hedman K, Hyypiä T, Lah denperä R, et al. Etiological diagnosis of childhood pneumonia by use of transthoracic needle aspiration and modern microbiological methods. Clin Infect Dis 2002;34:583-90.
10. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009;22:240-73.
11. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34.
12. Mühlradt PF, Kiess M, Meyer H, Süssmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997;185:1951-8.
13. Zuo LL, Wu YM, You XX. Mycoplasma lipoproteins and Toll-like receptors. J Zhejiang Univ Sci B 2009;10:67-76.
14. Narita M, Tanaka H, Yamada S, Abe S, Ariga T, Sakiyama Y. Signi ficant role of interleukin-8 in pathogenesis of pulmonary disease due to Mycoplasma pneumoniae infection. Clin Diagn Lab Immunol 2001; 8:1028-30.
15. Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB, et al. Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile. Infect Immun 2001;69:3869-76.
16. Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev 2004; 15:157-68.
17. Denny FW, Taylor-Robinson D, Allison AC. The role of thymusdependent immunity in Mycoplasma pulmonis infections of mice. J Med Microbiol 1972;5:327-36.
18. Tanaka H, Honma S, Abe S, Tamura H. Effects of interleukin-2 and cyclosporin A on pathologic features in Mycoplasma pneumonia. Am J Respir Crit Care Med 1996;154(6 Pt 1):1908-12.
19. Lee KY, Rhim JW, Kang JH. Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: a need for early immune-modulators for severe cases. Med Hypotheses 2011;76:64-9.
20. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41:263-8.
21. Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, Lee JS, et al. Difference of clinical features in childhood Mycoplasma pneumonia pneumonia. BMC Pediatr 2010;10:48.
22. Kim JW, Seo HK, Yoo EG, Park SJ, Yoon SH, Jung HY, et al. Myco plasma pneumoniae pneumonia in Korean children, from 1979 to 2006a meta-analysis. Korean J Pediatr 2009;52:315-23.
23. Lee SH, Noh SM, Lee KY, Lee HS, Hong JH, Lee MH, et al. Clinicoepidemiologic study of Mycoplasma pneumoniae pneumonia (1993 through 2003). Korean J Pediatr 2005;48:154-7.
24. Brunner H, Prescott B, Greenberg H, James WD, Horswood RL, Chanock RM. Unexpectedly high frequency of antibody to Mycoplasma pneumoniae in human sera as measured by sensitive techniques. J Infect Dis 1977;135:524-30.
25. Sasaki T, Kenri T, Okazaki N, Iseki M, Yamashita R, Shintani M, et al. Epidemiological study of Mycoplasma pneumoniae infections in Japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. J Clin Microbiol 1996;34:447-9.
26. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of communityacquired pneumonia. J Infect Chemother 2010;16:78-86.
27. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis 2010;67:355-8.
28. Dumke R, von Baum H, Lück PC, Jacobs E. Occurrence of macrolideresistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect 2010;16:613-6.
29. Oh CE, Choi EH, Lee HJ. Detection of genetic mutations associated with macrolide resistance of Mycoplasma pneumoniae. Korean J Pediatr 2010;53:178-83.
30. Hong KB, Lee SY, Choi EH, Lee J, Ahn YM, Lee HJ. Prevalence of genetic mutations associated with macrolide resistance of Mycoplasma pneumoniae in Korea. In: Program and abstracts of the 2011 Autumn Meeting of the Korean Society for Pediatric Infectious Diseases; 2011 Nov 12; Seoul: Korean Society of Pediatric Infectious Disease, 2011:7.
31. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006;50:709-12.
32. Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother 2009;15:380-3.
33. Narita M. Two unexpected phenomena in macrolide-resistant Myco plasma pneumoniae infection in Japan and the unique biological charac teristics of Mycoplasma pneumoniae. J Infect Chemother 2011;17:735-6.
34. Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest 2007;132:1962-6.
35. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother 2010;16:162-9.
36. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the gold standard. J Clin Microbiol 2005;43:2277-85.
37. Loens K, Goossens H, Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods. Eur J Clin Microbiol Infect Dis 2010;29:1055-69.
38. Martínez MA, Ruiz M, Zunino E, Luchsinger V, Avendaño LF. Detection of Mycoplasma pneumoniae in adult community-acquired pneumonia by PCR and serology. J Med Microbiol 2008;57(Pt 12):1491-5.
39. Zhang L, Zong ZY, Liu YB, Ye H, Lv XJ. PCR versus serology for diagnosing Mycoplasma pneumoniae infection: a systematic review & meta-analysis. Indian J Med Res 2011;134:270-80.
40. Youn YS, Lee KY, Hwang JY, Yim JW, Kang JH, Lee JS. Comparison of diagnostic methods and the changes of IgG subclasses in children with Mycoplasma pneumoniae pneumonia. Pediatr Allergy Respir Dis 2009;19:137-45.
41. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, Bartelds AI, Heijnen ML, Dankert J. Results of molecular detection of Mycoplasma pneu moniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs. J Infect Dis 2001;183:675-8.
42. Shames JM, George RB, Holliday WB, Rasch JR, Mogabgab WJ. Comparison of antibiotics in the treatment of mycoplasmal pneumonia. Arch Intern Med 1970;125:680-4.
43. McCracken GH Jr. Current status of antibiotic treatment for Mycoplasma pneumoniae infections. Pediatr Infect Dis 1986;5:167-71.
44. Mulholland S, Gavranich JB, Chang AB. Antibiotics for communityacquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 2010;(7): CD004875.
45. Miyashita N, Maruyama T, Kobayashi T, Kobayashi H, Taguchi O, Kawai Y, et al. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother 2011;17:114-8.
46. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 2011;17:1079-82.
47. Kosugi Y, Katsura H. A case of fulminant Mycoplasma pneumoniae pneumonia despite adequate antibiotic treatment. Nihon Kokyuki Gakkai Zasshi 2009;47:471-5.
48. Kim DH, Lee KY, Kim MS, Youn YS, Hwang JY, Rhim JW, et al. Corticosteroid treatment in siblings affected with severe Mycoplasma pneumoniae pneumonia. Infect Chemother 2009;41:190-5.
49. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 2008;57:223-8.
50. Miyashita N, Obase Y, Ouchi K, Kawasaki K, Kawai Y, Kobashi Y, et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 2007;56(Pt 12):1625-9.
51. Lu A, Wang L, Zhang X, Zhang M. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid. Pediatr Pulmonol 2011;46:1093-7.
52. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008;198:1180-8.
53. Hirao S, Wada H, Nakagaki K, Saraya T, Kurai D, Mikura S, et al. Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone. FEMS Immunol Med Microbiol 2011;62:182-9.